Rebecca L Ruebner1, Bernard S Kaplan, Lawrence Copelovitch. 1. Division of Nephrology, Department of Pediatrics, The Children's Hospital of Philadelphia, 1 Main, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA.
Abstract
UNLABELLED: Atypical hemolytic uremic syndrome (HUS) refers to the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury in the absence of Shiga toxin-producing Escherichia coli exposure or Streptococcus pneumoniae infection. Currently, approximately 50 % of the atypical cases have demonstrable mutations in complement regulatory proteins. Historically, the diagnosis of atypical HUS portends a poor prognosis with a high rate of disease recurrence, progression to end-stage renal disease, and death. However, it is now evident that atypical HUS actually encompasses a heterogeneous group of disorders, and there are reports suggesting that some cases of atypical HUS have a favorable prognosis, similar to that of diarrhea-associated disease. We present three patients with the atypical HUS phenotype who had complete renal recovery and no disease recurrence. We believe it is important to distinguish those cases of atypical HUS associated with disorders of complement regulatory proteins from other idiopathic causes of nondiarrheal HUS given the implications for prognosis and treatment. CONCLUSION: Given the heterogeneous nature and variable prognosis of atypical HUS, treatment should be carefully considered prior to the use of long-term plasma therapy and/or eculizumab.
UNLABELLED: Atypical hemolytic uremic syndrome (HUS) refers to the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury in the absence of Shiga toxin-producing Escherichia coli exposure or Streptococcus pneumoniae infection. Currently, approximately 50 % of the atypical cases have demonstrable mutations in complement regulatory proteins. Historically, the diagnosis of atypical HUS portends a poor prognosis with a high rate of disease recurrence, progression to end-stage renal disease, and death. However, it is now evident that atypical HUS actually encompasses a heterogeneous group of disorders, and there are reports suggesting that some cases of atypical HUS have a favorable prognosis, similar to that of diarrhea-associated disease. We present three patients with the atypical HUS phenotype who had complete renal recovery and no disease recurrence. We believe it is important to distinguish those cases of atypical HUS associated with disorders of complement regulatory proteins from other idiopathic causes of nondiarrheal HUS given the implications for prognosis and treatment. CONCLUSION: Given the heterogeneous nature and variable prognosis of atypical HUS, treatment should be carefully considered prior to the use of long-term plasma therapy and/or eculizumab.
Authors: Lothar Bernd Zimmerhackl; Johannes Hofer; Gérard Cortina; Walter Mark; Reinhard Würzner; Therese C Jungraithmayr; Gus Khursigara; Kay O Kliche; Wolfgang Radauer Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink Journal: N Engl J Med Date: 2009-01-29 Impact factor: 91.245
Authors: N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl Journal: Kidney Int Date: 2006-06-14 Impact factor: 10.612
Authors: C Wehling; O Amon; M Bommer; B Hoppe; K Kentouche; G Schalk; R Weimer; M Wiesener; B Hohenstein; B Tönshoff; R Büscher; H Fehrenbach; Ö-N Gök; M Kirschfink Journal: Clin Exp Immunol Date: 2016-11-25 Impact factor: 4.330